{"id":60559,"date":"2026-03-23T15:18:28","date_gmt":"2026-03-23T07:18:28","guid":{"rendered":"https:\/\/flcube.com\/?p=60559"},"modified":"2026-03-23T15:18:29","modified_gmt":"2026-03-23T07:18:29","slug":"hengrui-pharmas-shr-3836-wins-nmpa-approval-for-multiple-myeloma-first-in-class-anti-tumor-agent-enters-clinical-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=60559","title":{"rendered":"Hengrui Pharma&#8217;s SHR-3836 Wins NMPA Approval for Multiple Myeloma \u2013 First-in-Class Anti-Tumor Agent Enters Clinical Development"},"content":{"rendered":"\n<p><strong>Jiangsu Hengrui Pharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600276:SHA\">SHA: 600276<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/1276:HKG\">HKG: 1276<\/a>) announced that its <strong>independently developed drug candidate SHR-3836 Injection<\/strong> has received <strong>NMPA clinical trial approval<\/strong> for <strong>Multiple Myeloma (MM)<\/strong> \u2013 marking entry into human studies for a <strong>first-in-class anti-tumor agent<\/strong> with <strong>no marketed drugs of the same class globally<\/strong>, positioning Hengrui at the forefront of novel oncology mechanism exploration.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>SHR-3836 Injection<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276)<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Clinical trial approval (IND)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Multiple Myeloma (MM) \u2013 monotherapy evaluation<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Innovative anti-tumor agent<\/td><\/tr><tr><td><strong>Global Status<\/strong><\/td><td><strong>First-in-class<\/strong> \u2013 no marketed drugs of same class in China or internationally<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-amp-strategic-significance\">Product Profile &amp; Strategic Significance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>SHR-3836 Injection<\/strong> \u2013 <strong>independently developed<\/strong> by Hengrui Pharma<\/li>\n\n\n\n<li><strong>Therapeutic Class:<\/strong> <strong>Novel anti-tumor mechanism<\/strong> (specific target undisclosed)<\/li>\n\n\n\n<li><strong>Development Status:<\/strong><\/li>\n\n\n\n<li><strong>Preclinical validation:<\/strong> Complete<\/li>\n\n\n\n<li><strong>Clinical entry:<\/strong> Phase I initiation approved<\/li>\n\n\n\n<li><strong>Global differentiation:<\/strong> <strong>No competitive marketed agents<\/strong> \u2013 blue ocean opportunity<\/li>\n\n\n\n<li><strong>Indication Strategy:<\/strong> <strong>Multiple Myeloma<\/strong> \u2013 monotherapy evaluation in relapsed\/refractory setting<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-multiple-myeloma-market-context\">Multiple Myeloma Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Dimension<\/th><th>Current Landscape<\/th><th>SHR-3836 Opportunity<\/th><\/tr><\/thead><tbody><tr><td><strong>Standard of Care<\/strong><\/td><td>Proteasome inhibitors (bortezomib, carfilzomib), immunomodulatory agents (lenalidomide, pomalidomide), anti-CD38 mAbs (daratumumab), CAR-T (ide-cel, cilta-cel)<\/td><td>Novel mechanism may address resistance to existing classes; potential for combination or sequencing strategies<\/td><\/tr><tr><td><strong>Unmet Need<\/strong><\/td><td>High relapse rates; triple-class refractory MM has limited effective options<\/td><td>First-in-class agent offers new therapeutic avenue for heavily pretreated patients<\/td><\/tr><tr><td><strong>Market Size<\/strong><\/td><td>Global MM therapeutics ~US$22 billion annually; China ~RMB8-10 billion<\/td><td>Significant commercial opportunity if clinical efficacy demonstrated<\/td><\/tr><tr><td><strong>Competitive Intensity<\/strong><\/td><td>Crowded with established mechanisms; innovation focused on bispecifics, ADCs, CAR-T<\/td><td>SHR-3836&#8217;s novel class differentiation provides potential competitive moat<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Hengrui Oncology Pipeline Validation:<\/strong> SHR-3836 joins <strong>SHR-A1811 (HER2 ADC)<\/strong>, <strong>SHR-1316 (PD-L1)<\/strong>, <strong>SHR-1701 (PD-L1\/TGF-\u03b2 bispecific)<\/strong> in Hengrui&#8217;s innovative oncology portfolio; first-in-class status demonstrates <strong>internal discovery capabilities<\/strong> beyond fast-follower strategies.<\/li>\n\n\n\n<li><strong>Multiple Myeloma Strategic Focus:<\/strong> MM represents high-unmet-need hematologic malignancy with durable remission challenge; novel mechanism agent may qualify for <strong>Breakthrough Therapy Designation<\/strong> and <strong>accelerated approval pathways<\/strong> upon demonstration of efficacy in relapsed\/refractory population.<\/li>\n\n\n\n<li><strong>Clinical Development Trajectory:<\/strong> Phase I safety\/dose-finding expected <strong>H2 2026<\/strong>; proof-of-concept efficacy data <strong>2027-2028<\/strong>; potential for <strong>combination studies<\/strong> with established MM agents (daratumumab, IMiDs) to enhance durability of response.<\/li>\n\n\n\n<li><strong>Global Partnership Optionality:<\/strong> First-in-class status with China IND approval creates <strong>licensing attractiveness<\/strong> for global pharma seeking novel oncology mechanisms; potential deal structure: <strong>US$200-400 million upfront<\/strong> + milestones\/royalties for ex-China rights upon Phase I data.<\/li>\n\n\n\n<li><strong>Manufacturing &amp; Scale-Up:<\/strong> Novel mechanism may require specialized manufacturing capabilities; Hengrui&#8217;s established biologics and small-molecule infrastructure supports clinical supply; commercial scale-up partnership assessment contingent on Phase II efficacy signals.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, mechanism validation, and commercial expectations for SHR-3836. Actual results may differ due to risks including safety findings in first-in-human studies, competitive dynamics in the evolving multiple myeloma landscape, and manufacturing challenges for novel therapeutic classes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026032001048_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026032001048_c.\"><\/object><a id=\"wp-block-file--media-94bc6c74-5a77-4eb6-a297-34d17f8769c7\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026032001048_c.pdf\">2026032001048_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026032001048_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-94bc6c74-5a77-4eb6-a297-34d17f8769c7\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that its independently developed drug&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,62,2586,4228,852],"class_list":["post-60559","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-hengrui-pharmaceuticals","tag-hkg-1276","tag-sha-600276"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hengrui Pharma&#039;s SHR-3836 Wins NMPA Approval for Multiple Myeloma \u2013 First-in-Class Anti-Tumor Agent Enters Clinical Development - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that its independently developed drug candidate SHR-3836 Injection has received NMPA clinical trial approval for Multiple Myeloma (MM) \u2013 marking entry into human studies for a first-in-class anti-tumor agent with no marketed drugs of the same class globally, positioning Hengrui at the forefront of novel oncology mechanism exploration.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=60559\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hengrui Pharma&#039;s SHR-3836 Wins NMPA Approval for Multiple Myeloma \u2013 First-in-Class Anti-Tumor Agent Enters Clinical Development\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that its independently developed drug candidate SHR-3836 Injection has received NMPA clinical trial approval for Multiple Myeloma (MM) \u2013 marking entry into human studies for a first-in-class anti-tumor agent with no marketed drugs of the same class globally, positioning Hengrui at the forefront of novel oncology mechanism exploration.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=60559\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-23T07:18:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-23T07:18:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60559#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60559\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hengrui Pharma&#8217;s SHR-3836 Wins NMPA Approval for Multiple Myeloma \u2013 First-in-Class Anti-Tumor Agent Enters Clinical Development\",\"datePublished\":\"2026-03-23T07:18:28+00:00\",\"dateModified\":\"2026-03-23T07:18:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60559\"},\"wordCount\":485,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"Hengrui Pharmaceuticals\",\"HKG: 1276\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=60559#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60559\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=60559\",\"name\":\"Hengrui Pharma's SHR-3836 Wins NMPA Approval for Multiple Myeloma \u2013 First-in-Class Anti-Tumor Agent Enters Clinical Development - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-23T07:18:28+00:00\",\"dateModified\":\"2026-03-23T07:18:29+00:00\",\"description\":\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that its independently developed drug candidate SHR-3836 Injection has received NMPA clinical trial approval for Multiple Myeloma (MM) \u2013 marking entry into human studies for a first-in-class anti-tumor agent with no marketed drugs of the same class globally, positioning Hengrui at the forefront of novel oncology mechanism exploration.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60559#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=60559\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60559#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hengrui Pharma&#8217;s SHR-3836 Wins NMPA Approval for Multiple Myeloma \u2013 First-in-Class Anti-Tumor Agent Enters Clinical Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hengrui Pharma's SHR-3836 Wins NMPA Approval for Multiple Myeloma \u2013 First-in-Class Anti-Tumor Agent Enters Clinical Development - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that its independently developed drug candidate SHR-3836 Injection has received NMPA clinical trial approval for Multiple Myeloma (MM) \u2013 marking entry into human studies for a first-in-class anti-tumor agent with no marketed drugs of the same class globally, positioning Hengrui at the forefront of novel oncology mechanism exploration.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=60559","og_locale":"en_US","og_type":"article","og_title":"Hengrui Pharma's SHR-3836 Wins NMPA Approval for Multiple Myeloma \u2013 First-in-Class Anti-Tumor Agent Enters Clinical Development","og_description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that its independently developed drug candidate SHR-3836 Injection has received NMPA clinical trial approval for Multiple Myeloma (MM) \u2013 marking entry into human studies for a first-in-class anti-tumor agent with no marketed drugs of the same class globally, positioning Hengrui at the forefront of novel oncology mechanism exploration.","og_url":"https:\/\/flcube.com\/?p=60559","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-23T07:18:28+00:00","article_modified_time":"2026-03-23T07:18:29+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=60559#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=60559"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hengrui Pharma&#8217;s SHR-3836 Wins NMPA Approval for Multiple Myeloma \u2013 First-in-Class Anti-Tumor Agent Enters Clinical Development","datePublished":"2026-03-23T07:18:28+00:00","dateModified":"2026-03-23T07:18:29+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=60559"},"wordCount":485,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Clinical trial approval \/ initiation","Hengrui Pharmaceuticals","HKG: 1276","SHA: 600276"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=60559#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=60559","url":"https:\/\/flcube.com\/?p=60559","name":"Hengrui Pharma's SHR-3836 Wins NMPA Approval for Multiple Myeloma \u2013 First-in-Class Anti-Tumor Agent Enters Clinical Development - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-23T07:18:28+00:00","dateModified":"2026-03-23T07:18:29+00:00","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that its independently developed drug candidate SHR-3836 Injection has received NMPA clinical trial approval for Multiple Myeloma (MM) \u2013 marking entry into human studies for a first-in-class anti-tumor agent with no marketed drugs of the same class globally, positioning Hengrui at the forefront of novel oncology mechanism exploration.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=60559#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=60559"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=60559#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hengrui Pharma&#8217;s SHR-3836 Wins NMPA Approval for Multiple Myeloma \u2013 First-in-Class Anti-Tumor Agent Enters Clinical Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60559","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=60559"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60559\/revisions"}],"predecessor-version":[{"id":60562,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60559\/revisions\/60562"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=60559"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=60559"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=60559"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}